Press releases

Filter by year:

GeNeuro Announces the Approval of all Resolutions proposed at the AGM

Geneva, Switzerland, May 28, 2020 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced the approval by shareholders of all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2020.

GeNeuro: financial information and business update for the first quarter 2020

Geneva, Switzerland, April 27, 2020 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), today reported on its 2020 first quarter cash position and issued a business update.

GeNeuro appoints MS clinical development expert Dr. David Leppert as Chief Medical Officer

Geneva, Switzerland, April 21, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis , today announces the appointment of the experienced medical and industry professional Prof. David Leppert, MD and Professor of Neurology, as Chief Medical Officer.

GeNeuro Reports 2019 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 7, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today reported its full-year results for the year ended December 31, 2019 and provided a corporate update

GeNeuro Phase 2 multiple sclerosis trial update

Geneva, Switzerland, March 19, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced the temporary postponement of its planned Phase 2 trial of temelimab in multiple sclerosis (MS) at the Karolinska Institutet’s Academic Specialist Center (ASC), Stockholm, Sweden, to prioritize healthcare resources behind the fight of COVID-19 and to reduce the risk for MS patients.

GeNeuro: successful €17.5 million private placement

Geneva, Switzerland, January 31, 2020 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases (the “Company”), today announced the successful completion of a €17.5 million international private placement only to certain qualified and institutional investors.

GeNeuro: financial information and business update for the fourth quarter 2019

Geneva, Switzerland, January 30, 2020 – 6:00pm CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced its cash position at December 31, 2019, issued a business update and provided an outlook on its 2020 activities.

GeNeuro: upcoming investor meetings in San Francisco during the J.P. Morgan Healthcare Conference and in Paris at Biomed Event

Geneva, Switzerland, January 9, 2020 – 5:50pm CET - GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases will participate to the LifeSci Advisors Corporate Access Event from January 13 to 16, 2020, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.


Results 1-8 of 8